February 2, 2016 - The Institute for Clinical and Economic Review (ICER) announced today that it will develop a report assessing the comparative effectiveness and value of diabetes prevention programs. The report will be the subject of the June 24, 2016 public meeting of the California Technology Assessment Forum (CTAF).
Providing credible, evidence-based information about medical technologies, treatments, and models of care
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), reviews objective evidence reports and holds public meetings to develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. View a snapshot of how we do our drug reviews and how stakeholder input is incorporated.
December 21, 2015
February 12, 2016
Insulin Degludec (Tresiba®, Novo Nordisk) for Diabetes and Mepolizumab (Nucala®, GlaxoSmithKline) for Asthma
June 24, 2016
TBD, Southern California
Sign up to receive email notifications of upcoming CTAF meetings and new assessments. All fields required.